LEXEO THERAPEUTICS INC (LXEO)
Health Care · genetic medicine / biotechnology · NASDAQ
Lexeo Therapeutics is a clinical-stage genetic medicine company developing pioneering gene therapies for cardiovascular diseases with high unmet needs.
What LEXEO THERAPEUTICS INC does
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on developing gene therapies for genetically defined cardiovascular diseases. The company utilizes a portfolio of therapeutic candidates, including AAV-based gene therapies, to address the underlying genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy.
Recent developments
In June 2026, the company initiated the SUNRISE-FA 2 pivotal trial for LX2006. In August 2026, the FDA granted RMAT designation to LX2020 for the treatment of PKP2-ACM.
From LEXEO THERAPEUTICS INC's filing of 2026-08-12.
Themes: gene therapy, cardiovascular medicine, rare diseases
Fundamentals
- Price$3.00 as of 2026-10-21 close
- Market cap$246M as of 2026-08-10 (share count; price 2026-10-21)
- 1-year return-68.8% 2025-10-21 close $9.60 → 2026-10-21 close $3.00
- P/En/a negative earnings
- Net margin-9063.8% FY2022, SEC XBRL
- ROE-40.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta2.01 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How LXEO compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$28M | -$26M | -$0.30 | -$18M† | $7000† |
| Q1 FY2026 2026-03-31 | -$22M | -$20M | -$0.25 | -$21M | $35000 |
| Q4 FY2025 2025-12-31 | -$23M† | -$21M† | -$0.14† | -$20M† | $0† |
| Q3 FY2025 2025-09-30 | -$22M | -$20M | -$0.33 | -$30M† | $289000† |
| Q2 FY2025 2025-06-30 | -$31M | -$26M | -$0.60 | -$27M† | — |
| Q1 FY2025 2025-03-31 | -$34M | -$33M | -$0.99 | -$22M | — |
| Q4 FY2024 2024-12-31 | -$27M† | -$26M† | -$0.78† | -$28M† | $0† |
| Q3 FY2024 2024-09-30 | -$32M | -$29M | -$0.89 | -$18M† | $83000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$93M
- Short-term investments$119M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How LEXEO THERAPEUTICS INC looks technically
LEXEO THERAPEUTICS INC (LXEO) is trading 46.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 139 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 6 trading days ago. It is 72.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 46.1% below its 200-day average, the long-term trend line — a long-term downtrend | -46.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.04 | $4.04 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.57 | $5.57 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 19 calendar days ago — the swings before that are what the structure reading is measured on | 19 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.689. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 139 trading days ago — a "death cross", a bearish long-term signal | 139 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control | 33.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.55 to $3.69) — its "stochastic" reading is 40 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 39.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.99 | $10.99 |
|---|---|---|
| From the 52-week high | it is 72.7% below its 52-week high (its highest price of the past year) | -72.7% |
| Above the 52-week low | it is 17.6% above its 52-week low (its lowest price of the past year) | +17.6% |
| Below the 52-week high | it is 72.7% below its highest point of the past year | 72.7% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $22.33 (set on 2024-01-18) | $22.33 |
| Given back of the 52-week move | over the past year its closes ranged ($2.63 to $10.63), and it has recovered only a small part of its fall from last year’s high — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.57 to $7.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.6% |
| From the all-time high | it is 86.6% below its all-time high | -86.6% |
| Nearest price level | it is trading 20.1% below a resistance level at $3.60 — a price it turned at three times since 2025-05-20, most recently on 2025-07-25. Since 2024-10-21 it has 0 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +20.1% |
| All-time low | its lowest closing price on record is $1.45 (set on 2025-04-07) | $1.45 |
| Above the all-time low | it is 106.9% above its all-time low | +106.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 80% of the past ~6 months) | 80th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2574 between its high and its low — about 8.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2574 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.55 and $3.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.55 – $3.14 – $3.73 |
| Typical daily range (% of price) | its price moves about 8.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.6% |
| Stretch from the 200-day average | it is trading 10.0 daily ranges below its 200-day average price (46.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Gap filled | a 5.6% gap up opened on 2026-09-22 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.4 percentage points (the stock lost 26.5% while the market lost 0.1%) | -26.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 38.9 percentage points (the stock lost 35.6% while the market gained 3.3%) | -38.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 62.1 percentage points (the stock lost 52.3% while the market gained 9.8%) | -62.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 83.9 percentage points (the stock lost 68.8% while the market gained 15.2%) | -83.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.1% of the share price. | -34.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 43% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.31 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -43.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.74 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -19.8% |
Price levels it has turned at before
LXEO last closed at $3.00 on 2026-10-21. Since 2024-10-21 it has turned at 0 prices below its last close and 15 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.60 | Resistance | 20.1% above the last close | turned there three times · 2025-05-20 to 2025-07-25 |
| $4.01 | Resistance | 33.7% above the last close | turned there three times · 2026-06-11 to 2026-09-15 |
| $4.33 | Resistance | 44.3% above the last close | turned there twice · 2025-08-15 to 2026-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.69.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.69.
This reading has stood for 9 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$20.30 range $9.00 – $30.00; median $20.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LXEO
- Consensus EPS estimate-$0.3229 next reporting period, as of 2026-10-17
- Estimate change, 30 days$0.00 from -$0.3229, on 2026-09-12, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no approved products and has incurred significant losses since inception.","The development of novel gene therapies is subject to a complex, uncertain, and rigorous regulatory landscape.","The company requires ongoing capital raises to fund research and development and may face dilution or operational constraints."]
What changed in the latest 10-Q
AI-assisted comparison of LXEO's 10-Q filed 2026-08-12 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) adds under LX2006 Regulatory Alignment: 'In June 2026, we announced that we have finalized the SUNRISE-FA 2 pivotal study protocol and SAP for LX2006, each incorporating the FDA's feedback to date and intended to support a BLA submission to the FDA in the first half of 2028 under the accelerated approval pathway. The SUNRISE-FA 2 study was initiated in June 2026. We are continuing to engage with the FDA regarding the confirmatory evidence strategy for the SUNRISE-FA 2 study.'
- Newer filing (2026-08-12) adds under LX2020 Interim Clinical Data Updates: 'In August 2026, we announced that we received Regenerative Medicine Advanced Therapy, or RMAT, designation for LX2020 for the treatment of PKP2-ACM from the FDA based on recent interim data from our ongoing Phase I/II clinical trial in PKP2-ACM. RMAT designation provides opportunities for increased FDA interaction and may help expedite the development of LX2020.'
- Newer filing (2026-08-12) adds parenthetical clarification to LX2020 PKP2 protein expression bullet: '(previously reported 93% due to a calibration error)' after 'mean increase of 90%' in the low-dose cohort.
- Removed:
- Older filing (2026-05-11) includes a paragraph under LX2006 Regulatory Alignment beginning 'In February 2025, we announced further alignment on elements of the accelerated development pathway following a Type B Regenerative Medicine Advanced Therapy, or RMAT, meeting...' that is not present in the newer filing.
- Older filing (2026-05-11) includes a paragraph under LX2006 Regulatory Alignment beginning 'In October 2025, in response to our questions regarding the possibility of a faster path to a Biologics License Application, or BLA, the FDA indicated openness to a BLA submission for accelerated approval...' that is not present in the newer filing.
- Older filing (2026-05-11) states under LX2006 Regulatory Alignment: 'We are in contact with the FDA and are awaiting final feedback on the study protocol. We plan to provide an update when the protocol and SAP are finalized.' This sentence is not present in the newer filing.
- Older filing (2026-05-11) describes LX2006 as 'currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial.' This sentence is not present in the newer filing.
- Reworded:
- Newer filing (2026-08-12) appears to have a numbering or page marker change ('23' vs '22') that is apparently a pagination artifact.
- Older filing (2026-05-11) text appears truncated at the end of the provided excerpt ('right ve...'), so later sections including the full 'Each of our gene therapy candidates' continuation could not be fully compared.
- Notes:
- The provided older filing text is truncated mid-sentence ('...right ve'), so changes after that point cannot be assessed.
- Only the provided excerpts of each filing were compared; no other sections of either filing were reviewed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 3 sells ($43228) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 9 sells ($323338) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LXEO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LXEO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 18,282,863
- Reported value $85,106,729
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LXEO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LXEO had 19,246,976 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LXEO had 23.5% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.04 days to cover at the same settlement.
- Reported short interest (shares) 19,246,976
- Short interest (% of shares outstanding) 23.5%
- Prior settlement (shares) 20,627,916
- Reported change -6.69%
- Days to cover (reported) 9.04
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Rocket Pharmaceuticals (RCKT)
- Sarepta Therapeutics (SRPT)
- Intellia Therapeutics (NTLA)
- Beam Therapeutics (BEAM)
- Editas Medicine (EDIT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LXEO vs…
LEXEO THERAPEUTICS INC is found in…
Frequently asked questions
What does LEXEO THERAPEUTICS INC (LXEO) do?
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on developing gene therapies for genetically defined cardiovascular diseases. The company utilizes a portfolio of therapeutic candidates, including AAV-based gene therapies, to address the underlying genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy.
What sector is LEXEO THERAPEUTICS INC (LXEO) in?
LEXEO THERAPEUTICS INC (LXEO) is classified in the Health Care sector. Its industry is genetic medicine / biotechnology. It trades on NASDAQ.
Who are LEXEO THERAPEUTICS INC's (LXEO) competitors?
Notable peers of LEXEO THERAPEUTICS INC (LXEO) include Rocket Pharmaceuticals, Sarepta Therapeutics, Intellia Therapeutics, Beam Therapeutics and Editas Medicine. This peer set is informational only — not financial advice.
Is LEXEO THERAPEUTICS INC (LXEO) overbought or oversold right now?
LEXEO THERAPEUTICS INC (LXEO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LXEO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.